Insights Into Breast Cancer
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer. Insights on current treatment practice attitudes toward recently introduced and upcoming agents
![](https://www.aptitudehealth.com/wp-content/uploads/2019/12/Sushil-Bhardway-MD-Aptitude-Health-Moderator.jpg)
Meeting Moderator
Sushil Bhardwaj, MD
Good Samaritan Hospital Suffern, NY, USA
Look Inside This Report
Download a sample of this report and start discovering the insights
Report Snapshot
Insights on the following breast cancer therapies were obtained
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, AIs, mTOR inhibitors, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- A roundtable discussion, moderated by an Axess Oncology Network Physician, focusing on treatment of metastatic breast cancer was held on August 24, 2019, in Washington, DC, US
- Disease state and data presentations were developed in conjunction with a medical expert from the University of Pittsburgh
- The group of advisors comprised 14 community oncologists from the Northeast, US
- Data collection was accomplished through use of audience response system questioning and moderated discussion